PSMA Connect, a Healthcare Group Purchasing Organisation (GPO), and HealthIQ Solutions, a provider of remote patient care management and clinical technology, said on Monday that they have formed a new strategic provider alliance.
This alliance unite PSMA Connect's extensive supply chain cost savings with HealthIQ Solutions' continuous remote patient monitoring programs to help empower healthcare providers, optimise practice revenue, and improve clinical outcomes nationwide.
The companies say that their joint initiative addresses two of the most pressing challenges facing healthcare practices today: escalating operational costs, and the need for proactive, continuous care models. Through this partnership, medical practices and health systems gain access to significant volume-discounted pricing on essential medical-surgical supplies, equipment, pharmaceuticals, and vaccines, while simultaneously deploying turn-key Remote Patient Monitoring (RPM), Chronic Care Management (CCM), Advanced Primary Care Management (APCM) and specialised remote care solutions.
PSMA Connect partners with HealthIQ Solutions
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
Akeso presents positive results from registrational Phase III study of ivonescimab
US FDA grants orphan drug designation for Lundbeck's asedebart
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
Insilico Medicine doses first patient in Phase III trial of rentosertib
Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study